Tenderwize
Wróć do wyszukiwania

Non-exclusive drug discount agreement for Axitinib

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 34 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Axitinib (ATC-Code nach WHO: L01EK01)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No minimum purchase quantities; actual demand is unpredictable and dependent on patient numbers and prescriber behavior...

The buyer reserves the right to terminate the open-house model early if exclusive agreements are concluded. According t...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Conclusion of non-exclusive drug discount agreements for Axitinib (ATC L01EK01) under § 130a (8) SGB V.
  • Open-house model: any eligible pharmaceutical company can enter into the agreement during the participation period.
Pokaż pełne podsumowanie

Non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a (8) SGB V for the active ingredient Axitinib (ATC L01EK01) via an open-house model. The buyer is AOK PLUS for the regions of Saxony and Thuringia. Participation is open to all interested pharmaceutical companies meeting the conditions. No guaranteed purchase quantities. The contract runs until 30 September 2026. First submission deadline: 5 August 2025; subsequent submissions accepted periodically. Submitted documents are confidential.

Ryzyka

No minimum purchase quantities; actual demand is unpredictable and dependent on patient numbers and prescriber behavior...

The buyer reserves the right to terminate the open-house model early if exclusive agreements are concluded. According t...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined in § 4 (18) AMG for the offered medicinal products.
  • Company must have its seat in Germany, another EU member state, or an EEA state (§ 9 (2) AMG).

Eligibility

  • Must submit a declaration regarding non-exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

Award likely based on the discount rate specified in the confidential agreement, but not detailed in the notice.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive drug discount agreement for Axitinib

One lot covering the conclusion of non-exclusive discount agreements for Axitinib. Scope includes pharmaceutical products with ATC code L01EK01. Performance location: Dresden, Germany.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Aug 2025 - Sep 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

Award likely based on the discount rate specified in the confidential agreement, but not detailed in the notice.

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
14 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
459714-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3